Risk of COVID-19 infection, hospitalization and mortality in psoriasis patients treated with interleukin-17 inhibitors: A systematic review and meta-analysis

BACKGROUND: Coronavirus disease 2019 (COVID-19) have brought great disaster to mankind, and there is currently no globally recognized specific drug or treatment. Severe COVID-19 may trigger a cytokine storm, manifested by increased levels of cytokines including interleukin-17 (IL-17), so a new strat...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Meitong, Wang, Huijuan, Liu, Lu, Cui, Saijin, Huo, Xiangran, Xiao, Zhuoyun, Zhao, Yaning, Wang, Bin, Zhang, Guoqiang, Wang, Na
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9648142/
https://www.ncbi.nlm.nih.gov/pubmed/36389759
http://dx.doi.org/10.3389/fimmu.2022.1046352

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9648142/
https://www.ncbi.nlm.nih.gov/pubmed/36389759
http://dx.doi.org/10.3389/fimmu.2022.1046352

Ejemplares similares